Compared with LT7-SS-DOX, the DT7-SS-DOX conjugate had the advantages of much higher in vitro serum stability, more sustained reduction-responsive drug release behavior, and stronger tumor cell proliferation inhibitory activity, indicating that DT7 can be used as an excellent peptide ligand for constructing stable TfR targeted PDCs. This evidence concerns the gene TFRC and neoplasm.